The countdown to Brandweek is on! Join us, Sept. 12-16, to identify new growth opportunities, solve challenges and connect with power players. View the lineup and secure your pass.
In 2015, GlaxoSmithKlein and Novartis completed a deal worth more than $20 billion that combined the two companies' assets. In November of that year, various sources reported that the newly created company planned to launch a review of its agency partners to effectively reset its global relationships.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in